These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 24787449)

  • 1. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for rasburicase therapy in the context of G6PD deficiency genotype.
    Relling MV; McDonagh EM; Chang T; Caudle KE; McLeod HL; Haidar CE; Klein T; Luzzatto L;
    Clin Pharmacol Ther; 2014 Aug; 96(2):169-74. PubMed ID: 24787449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD Genotype.
    Gammal RS; Pirmohamed M; Somogyi AA; Morris SA; Formea CM; Elchynski AL; Oshikoya KA; McLeod HL; Haidar CE; Whirl-Carrillo M; Klein TE; Caudle KE; Relling MV
    Clin Pharmacol Ther; 2023 May; 113(5):973-985. PubMed ID: 36049896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rasburicase-Induced Methemoglobinemia in a Patient with Glucose-6- Phosphate Dehydrogenase Deficiency.
    Khan M; Paul S; Farooq S; Oo TH; Ramshesh P; Jain N
    Curr Drug Saf; 2017; 12(1):13-18. PubMed ID: 28078984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methemoglobinemia induced by rasburicase in a pediatric patient: a case report and literature review.
    Ng JS; Edwards EM; Egelund TA
    J Oncol Pharm Pract; 2012 Dec; 18(4):425-31. PubMed ID: 22190578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemolysis and methemoglobinemia secondary to rasburicase administration.
    Browning LA; Kruse JA
    Ann Pharmacother; 2005 Nov; 39(11):1932-5. PubMed ID: 16204390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review and drug therapy implications of glucose-6-phosphate dehydrogenase deficiency.
    Belfield KD; Tichy EM
    Am J Health Syst Pharm; 2018 Feb; 75(3):97-104. PubMed ID: 29305344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rasburicase causing severe oxidative hemolysis and methemoglobinemia in a patient with previously unrecognized glucose-6-phosphate dehydrogenase deficiency.
    Cheah CY; Lew TE; Seymour JF; Burbury K
    Acta Haematol; 2013; 130(4):254-9. PubMed ID: 23860572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of pre-emptive rapid testing for glucose-6-phosphate dehydrogenase deficiency prior to rasburicase administration at a tertiary care centre: A retrospective study.
    Ganapathi M; Campbell P; Ofori K; Aggarwal V; Francis RO; Kratz A
    Br J Clin Pharmacol; 2022 Sep; 88(9):4163-4170. PubMed ID: 35419830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. I.V. ascorbic acid for treatment of apparent rasburicase-induced methemoglobinemia in a patient with acute kidney injury and assumed glucose-6-phosphate dehydrogenase deficiency.
    Reeves DJ; Saum LM; Birhiray R
    Am J Health Syst Pharm; 2016 May; 73(9):e238-42. PubMed ID: 27099330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rasburicase-induced hemolytic anemia in previously undiagnosed G6PD deficiency.
    Ferguson D; Kovach AE
    Blood; 2018 Aug; 132(6):673. PubMed ID: 30093385
    [No Abstract]   [Full Text] [Related]  

  • 11. Methaemoglobinaemia in a G6PD-deficient child treated with rasburicase.
    Bontant T; Le Garrec S; Avran D; Dauger S
    BMJ Case Rep; 2014 Aug; 2014():. PubMed ID: 25115783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implications.
    Luzzatto L; Seneca E
    Br J Haematol; 2014 Feb; 164(4):469-80. PubMed ID: 24372186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rasburicase-induced haemolysis and methemoglobinemia: an ongoing issue.
    Madanat L; Schoenherr D; Wey E; Gupta R
    BMJ Case Rep; 2021 Mar; 14(3):. PubMed ID: 33727299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incorporating G6PD genotyping to identify patients with G6PD deficiency.
    Morris SA; Crews KR; Hayden RT; Takemoto CM; Yang W; Baker DK; Broeckel U; Relling MV; Haidar CE
    Pharmacogenet Genomics; 2022 Apr; 32(3):87-93. PubMed ID: 34693927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methemoglobinemia and hemolysis in a patient with G6PD deficiency treated with rasburicase.
    Sonbol MB; Yadav H; Vaidya R; Rana V; Witzig TE
    Am J Hematol; 2013 Feb; 88(2):152-4. PubMed ID: 22573495
    [No Abstract]   [Full Text] [Related]  

  • 16. Discussion on pharmacogenetic interaction in G6PD deficiency and methods to identify potential hemolytic drugs.
    Manganelli G; Fico A; Martini G; Filosa S
    Cardiovasc Hematol Disord Drug Targets; 2010 Jun; 10(2):143-50. PubMed ID: 20350285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update.
    Amstutz U; Henricks LM; Offer SM; Barbarino J; Schellens JHM; Swen JJ; Klein TE; McLeod HL; Caudle KE; Diasio RB; Schwab M
    Clin Pharmacol Ther; 2018 Feb; 103(2):210-216. PubMed ID: 29152729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concordance between glucose-6-phosphate dehydrogenase (G6PD) genotype and phenotype and rasburicase use in patients with hematologic malignancies.
    Robinson KM; Yang W; Haidar CE; Hankins JS; Jay DW; Kornegay N; Rubnitz JE; Broeckel U; Cheng C; Pui CH; Jeha S; Relling MV
    Pharmacogenomics J; 2019 Jun; 19(3):305-314. PubMed ID: 30206300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mortality following rasburicase-induced methemoglobinemia.
    Bucklin MH; Groth CM
    Ann Pharmacother; 2013 Oct; 47(10):1353-8. PubMed ID: 24259700
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.